Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/FJC.0000000000000836 http://scihub22266oqcxt.onion/10.1097/FJC.0000000000000836 32282502!7219860!32282502     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Cardiovasc+Pharmacol 2020 ; 75 (5): 359-367 Nephropedia Template TP {{tp|p=32282502|t=2020. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}{{32282502}} gab.com Text Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19) JO: J Cardiovasc Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32282502 #FOAvip A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequelae, such as myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions. Twit Text FOAVip Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19) ????J Cardiovasc Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32282502 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32282502 #FOAvip English Wikipedia <ref>{{Cite pmid|32282502}}</ref> Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19) #MMPMID32282502 Dixon DL; Van Tassell BW; Vecchie A; Bonaventura A; Talasaz AH; Kakavand H; D'Ascenzo F; Perciaccante A; Castagno D; Ammirati E; Biondi-Zoccai G; Stevens MP; Abbate A J Cardiovasc Pharmacol 2020[May]; 75 (5): 359-367 PMID32282502show ga A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequelae, such as myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions. |Betacoronavirus/isolation & purification[MESH] |COVID-19[MESH] |Cardiovascular Diseases/*drug therapy/metabolism/*virology[MESH] |Clinical Trials, Phase III as Topic[MESH] |Coronavirus Infections/*drug therapy/metabolism/virology[MESH] |Drug Interactions[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/metabolism/virology[MESH] |Randomized Controlled Trials as Topic[MESH]Cardiovascular Considerations in Treating Patients With Coronavirus Di(epmc).pdf DeepDyve Pubget Overpricing